This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Makes Perrigo (PRGO) a New Buy Stock
by Zacks Equity Research
Perrigo (PRGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Perrigo (PRGO) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Perrigo (PRGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Perrigo (PRGO) Misses on Q3 Earnings, Lowers Earnings View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.
Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -30.77% and -0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal
by Zacks Equity Research
Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.
Why Is Perrigo (PRGO) Up 7.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma
by Zacks Equity Research
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
Perrigo (PRGO) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -18.03% and -3.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo (PRGO) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Perrigo (PRGO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -10.71% and -0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.